Sun Pharma announces FDA tentative approval for generic Cymbalta

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Sun Pharmaceutical Industries Ltd. announced US FDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain

Sofinnova Partners Raises $750mn to Support Biotech Startups

J&J Buys Halda for $3bn to Own the Cell Death Platform

Pharma Grade Supplements vs. Food Grade Supplements

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

FDA Looking to Lower Drugs Cost for All Americans

Future-proof vial filling – How flexibility Along the Line Defines Success

How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing

Rethinking Real-World Data Partnerships: How to Fill Gaps Without Starting Over

Energy efficiency in pure steam generation: How small adjustments can lead…

Pharmacovigilance Systems Gaining Higher Ground with AI

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using…

New data from Elsevier finds one in three corporate researchers have…

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in…

API China Strengthens its Role as Asia’s Pharma Powerhouse

swop 2025: Celebrating Ten Years of Industry Growth

Sun Pharma announces FDA tentative approval for generic Cymbalta

Sofinnova Partners Raises $750mn to Support Biotech Startups

J&J Buys Halda for $3bn to Own the Cell Death Platform

Pharma Grade Supplements vs. Food Grade Supplements

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

Sofinnova Partners Raises $750mn to Support...

J&J Buys Halda for $3bn to...

How Automation is Transforming Pharmaceutical Packaging

Pharma Packaging Soars to $464B: Growth...

Sustainable Pharma Packaging: Future Trends and...

Pharma Packaging Equipment Market to Reach...

Sofinnova Partners Raises $750mn to Support Biotech Startups

J&J Buys Halda for $3bn to Own the Cell Death Platform

Pharma Grade Supplements vs. Food Grade Supplements

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

About us

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Sofinnova Partners Raises $750mn to Support Biotech Startups

J&J Buys Halda for $3bn to Own the Cell Death Platform